Drug
Pimasertib clinical trials
Also written MSC1936369B and AS703026.
Includes 2 studies of Pimasertib hydrochloride.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
14 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
EMD Serono (7) · Merck KGaA, Darmstadt, Germany (3) · Sanofi (2) · M.D. Anderson Cancer Center (1) · Day One Biopharmaceuticals, Inc. (1)
Often tested with
Tested in the same studies.
XL765 (1) · XL147 (1) · SAR405838 (1) · Bintrafusp alfa (1) · Tovorafenib (1) · Temsirolimus (1)
Studies
Open first, then newest update. How each study uses pimasertib is read from its arms, and is right about nine times in ten.
Testing it · 14
- Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04789668Written as Pimasertib
- Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsTerminatedPhase 1Day One Biopharmaceuticals, Inc.NCT07121829Written as Tovorafenib Drug: Pimasertib
- Trial of MSC1936369B in Subjects With Solid TumorsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT00982865Written as MSC1936369B
- Combination Trial of Pimasertib (MSC1936369B) With TemsirolimusTerminatedPhase 1EMD SeronoNCT01378377Written as Pimasertib
- Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaCompletedPhase 2EMD SeronoNCT01693068Written as Pimasertib
- A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as MonotherapyTerminatedPhase 1Merck KGaA, Darmstadt, GermanyNCT01668017Written as Pimasertib
- Trial of Pimasertib in Hematological MalignanciesTerminatedPhase 2EMD SeronoNCT00957580Written as Pimasertib
- Relative Bioavailability of Pimasertib in Cancer PatientsCompletedPhase 1EMD SeronoNCT01992874Written as Pimasertib Capsule (Part A)
- Oral Bioavailability and Mass Balance Trial With PimasertibCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT01713036Written as Pimasertib
- Trial of Gemcitabine With or Without MSC1936369B in Pancreatic CancerCompletedPhase 1/2EMD SeronoNCT01016483Written as Pimasertib
- Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1EMD SeronoNCT01390818Written as MSC1936369B (pimasertib)
- MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)TerminatedPhase 1/2EMD SeronoNCT01085331Written as Pimasertib
- Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1SanofiNCT01357330Written as MSC1936369B
- A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer PatientsCompletedPhase 1SanofiNCT01985191Written as Pimasertib
Codes
What other systems call pimasertib · ClinicalTrials.gg INT005662
- UNII (FDA) 6ON9RK82ALPIMASERTIBConfirmed FDA, Wikidata
- Wikidata Q27088393pimasertibConfirmed FDA, Wikidata
- NCI Thesaurus C84864PimasertibOne source FDA
- DrugBank DB14904One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6ON9RK82AL | PIMASERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088393 | pimasertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C84864 | Pimasertib | One source FDA |
| DrugBank | DB14904 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.